Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections.
about
Critical appraisal of rituximab in the maintenance treatment of advanced follicular lymphomaChallenges in the Role of Gammaglobulin Replacement Therapy and Vaccination Strategies for Hematological MalignancyImmune deficiency in chronic rhinosinusitis: screening and treatment.Is dosing of therapeutic immunoglobulins optimal? A review of a three-decade long debate in europeRituximab therapy has a rapid and durable response for refractory cytopenia in childhood-onset systemic lupus erythematosus.The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease.II Brazilian Consensus on the use of human immunoglobulin in patients with primary immunodeficiencies.Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: a single-center experience in 61 patients.Hypogammaglobulinemia and Poor Performance Status are Predisposing Factors for Vancomycin-Resistant Enterococcus Colonization in Patients with Hematological MalignanciesInfluence of R-CHOP Therapy on Immune System Restoration in Patients with B-Cell LymphomaPrimary vs. secondary antibody deficiency: clinical features and infection outcomes of immunoglobulin replacement.The risk of infections in hematologic patients treated with rituximab is not influenced by cumulative rituximab dosage - a single center experience.Immunoglobulin replacement therapy in secondary hypogammaglobulinemiaThe use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States.Immunreconstitution and infectious complications after rituximab treatment in children and adolescents: what do we know and what can we learn from adults?Diagnostic and therapeutic challenges of EBV-positive mucocutaneous ulcer: a case report and systematic review of the literature.Place in therapy of rituximab in the treatment of granulomatosis with polyangiitis and microscopic polyangiitis.Rituximab for the treatment of rheumatoid arthritis: an update.Preliminary analysis of mortality associated with rituximab use in autoimmune diseases.Beyond tumor necrosis factor inhibition: the expanding pipeline of biologic therapies for inflammatory diseases and their associated infectious sequelae.Hypogammaglobulinaemia after rituximab treatment-incidence and outcomes.Practical Management of Respiratory Comorbidities in Patients with Rheumatoid Arthritis.Bendamustine associated immune suppression and infections during therapy of hematological malignancies.Targeting B cells in relapsing-remitting multiple sclerosis: from pathophysiology to optimal clinical management.Natural IgM antibodies in the immune defence against neoehrlichiosis.Unintended Immunological Consequences of Biologic Therapy.Secondary immunodeficiency in lymphoproliferative malignancies.Prophylactic immunoglobulin therapy in secondary immune deficiency - an expert opinion.The safety profile of monoclonal antibodies for chronic lymphocytic leukemia.When to initiate immunoglobulin replacement therapy (IGRT) in antibody deficiency: a practical approach.Targeted Drugs as Maintenance Therapy after Autologous Stem Cell Transplantation in Patients with Mantle Cell Lymphoma.Rituximab for the treatment of follicular lymphoma.Hypogammaglobulinemia and risk of severe infection in kidney transplant recipients.Immunoglobulin levels and infection risk with rituximab induction for anti-neutrophil cytoplasmic antibody-associated vasculitis.Risk factors predisposing to the development of hypogammaglobulinemia and infections post-Rituximab.Dynamics of Epstein-Barr viral load after hematopoietic stem cell transplantation and effect of preemptive rituximab therapy.Facilitated subcutaneous immunoglobulin administration (fSCIg): a new treatment option for patients with secondary immune deficiencies.Kinetics of hematogones in bone marrow samples from patients with non-Hodgkin lymphomas treated with rituximab-containing regimens: a flow cytometric study.Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients.Impact of rituximab maintenance and maintenance schedule on prognosis in first-line treatment of follicular lymphoma. Retrospective analysis from Czech Lymphoma Study Group (CLSG) database.
P2860
Q26775837-5E9B9423-BC3D-46B2-A2E7-D9CB07578B4BQ28080304-414989D4-22E0-4F00-BC0A-4CA9F012D86BQ30248581-39807ABB-763F-4B1F-9625-6E79BCD80D01Q33419638-0C262F17-B73B-424B-A35A-F7C8688804CBQ33421410-2246F912-76C3-47EB-9464-88D693A028CEQ33683956-0093A965-6B8C-475D-BEFF-2ADE49900F72Q33692418-A43BD46C-9818-4E48-BA52-C7D72C9C198DQ33695997-50E47FEB-69EF-4CFC-A8ED-DB75A8CA3BFDQ33747832-58D302F6-1B86-4490-A619-0EE996FF0E84Q33787262-593E84E8-1367-4EA3-BF94-0193610F71BEQ33817252-CD160DD7-84CC-491C-AB72-1EBC2891E4C9Q34486116-D4633625-8588-4FC1-BA0E-6BE03F06AD31Q34652046-AB020897-199F-40A4-AAD4-B87D88259616Q34699650-B781912E-370C-4135-9619-A9FCF1E2BF8AQ35237511-161DF61B-FE14-46A2-A050-3B1C8062816EQ36846805-6C9B25BF-FB5B-4838-AA60-C4DC7D45FB07Q37031689-B839DB82-866C-4CF5-8AC8-5D16C0185B9CQ37444678-A0E77C3A-F774-4045-A501-57F0F6B7FA8CQ38154934-002418EB-15D0-4A52-8C47-49D53ECB14EBQ38192553-660884CB-E6F0-433D-B6E6-376A08EF7C39Q38207970-D28F7ADF-AFAB-4C7F-B2FF-AF4D2C8B1E63Q38642378-9F70260E-F0E9-4FD9-BA08-4261E87FB24AQ38676858-EC629CCA-28DD-4DE4-94DD-2C874DC5ADE0Q38690022-B3FA89F9-C3E3-4F4F-9C0B-1718AAE21ECAQ38691383-DA5B82E6-57F1-40F0-8E49-6D3C6D955956Q38871098-1A7A0AE8-A251-45D4-8078-8EFCEA6E370AQ38893343-4C68C09D-57AE-4DF8-A587-322696DDF8A2Q38896505-6CC626D3-AB12-40DD-ABF5-94FCB8B18EFEQ39018189-45F8BBDE-815C-4352-8B7C-8027DE3AE7C3Q39045194-51EB9EBA-4F78-4E0D-A75A-BB054B8B351DQ39175963-F6E3D399-3F3D-4F54-8216-33A6442FC77EQ39360775-C20CB6E8-1B9C-4766-B1ED-1197CBEE74C4Q39503723-6FF3C943-A06A-42EB-97B2-6EE1B1FB82C6Q40075352-3063DCB3-C8DE-41A1-9F44-E6F8AA9EDCB8Q40097140-54D400B4-EEC3-4C6B-9ACD-3F66391E3F1DQ40518920-F2F129F4-CE3B-49D8-8849-D01A86BA8210Q40683402-0E086B03-08A9-4A59-94D7-A497181C05F6Q40962973-4E67F54F-DFD0-49A2-AE9C-8DACA30D6614Q41096503-B5D48241-5F9D-4778-A429-3F457FB6416AQ41465999-D123DF9A-5F7C-4CC0-9D2D-142715071284
P2860
Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections.
description
2012 nî lūn-bûn
@nan
2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
name
Incidence of hypogammaglobulin ...... ulin for recurrent infections.
@ast
Incidence of hypogammaglobulin ...... ulin for recurrent infections.
@en
type
label
Incidence of hypogammaglobulin ...... ulin for recurrent infections.
@ast
Incidence of hypogammaglobulin ...... ulin for recurrent infections.
@en
prefLabel
Incidence of hypogammaglobulin ...... ulin for recurrent infections.
@ast
Incidence of hypogammaglobulin ...... ulin for recurrent infections.
@en
P2860
P1476
Incidence of hypogammaglobulin ...... bulin for recurrent infections
@en
P2093
Carla Casulo
Jocelyn Maragulia
P2860
P304
P356
10.1016/J.CLML.2012.11.011
P407
P577
2012-12-29T00:00:00Z